EMBOLUS-INDUCED BRANCH RETINAL ARTERY OCCLUSION WITH A PRESENTING BEST-CORRECTED VISUAL ACUITY OF &lt;6/12 AND VISUAL FIELD DEFECT

Hsu, Tsui Kang; Chen, Shih‐Jen; Lei, Jianqin; Wu, Zhifeng; Lin, Chih Ching; Chen, Mi Mi; Lin, Tzu‐Chin; Liu, Jorn Hon; Chao, Hsiao Ming

doi:10.1097/icb.0b013e3182852370

Cited by 7 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BRAO eyes that have poorer presenting corrected vision are unlikely to spontaneously improve in the vision and this could result in persistent retinal injury [43, 44]. Topical brimonidine and somatostatin had been shown to act as neuroprotectants and seem to attenuate morbidity due to background diabetic retinopathy (BDR) as well as any deterioration of BDR into PDR [45].…”

Section: Discussionmentioning

confidence: 99%

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Tan

Geng

Liu

et al. 2017

BMC Complement Altern Med

Self Cite

View full text Add to dashboard Cite

BackgroundRetinal ischemia-related eye diseases result in visual dysfunction. This study investigates the protective effects and mechanisms of Xue-Fu-Zhu-Yu decoction (XFZYD) with respect to retinal ischemia.MethodsRetinal ischemia (I) was induced in Wistar rats by a high intraocular pressure (HIOP) of 120 mmHg for 1 h, which was followed by reperfusion of the ischemic eye; the fellow untreated eye acted as a control. Electroretinogram (ERG), biochemistry and histopathology investigations were performed.ResultsSignificant ischemic changes occurred after ischemia including decreased ERG b-wave ratios, less numerous retinal ganglion cells (RGCs), reduced inner retinal thickness, fewer choline acetyltransferase (ChAT) labeled amacrine cell bodies, increased glial fibrillary acidic protein (GFAP) immunoreactivity and increased vimentin Müller immunolabeling. These were accompanied by significant increases in the mRNA/protein concentrations of vascular endothelium growth factor, hypoxia-inducible factor-1α, pyruvate kinase M2 and retinoblastoma-binding protein 2. The ischemic changes were concentration-dependently and significantly altered when XFZYD was given for seven consecutive days before or after retina ischemia, compared to vehicle. These alterations included enhanced ERG b-wave amplitudes, more numerous RGCs, enhanced inner retinal thickness, a greater number of ChAT immunolabeled amacrine cell bodies and decreased GFAP/vimentin immunoreactivity. Furthermore, decreased mRNA levels of VEGF, HIF-1α, PKM2, and RBP2 were also found. Reduced protein concentrations of VEGF, HIF-1α, PKM2, and RBP2 were also demonstrated. Furthermore, there was an inhibition of the ischemia-associated increased ratios (target protein/β-actin) in the protein levels of VEGF, HIF-1α, PKM2, and RBP2, which were induced by Shikonin, JIB-04 or Avastin.ConclusionXFZYD would seem to protect against well-known retinal ischemic changes via a synergistic inhibition of RBP2 and PKM2, as well as down-regulation of HIF-1α and a reduction in VEGF secretion.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-017-1857-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Tan

Geng

Liu

et al. 2017

BMC Complement Altern Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, in human BRAO studies, 46 % (24 of 52) of the eyes tested in the series reported by Mason et al [32] and 100 % (5 of 5) of eyes tested in the series reported by Hsu et al [33] were found to present with best corrected visual acuity (BCVA) values of <20/40. Furthermore, Mason et al [32] indicated that 75 % (18 of 24) of the untreated eyes with a poor presentation of BCVA (<20/40) had a final BCVA of <20/40.…”

Section: Discussionmentioning

confidence: 99%

Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase

Chao

Cheng

et al. 2016

Chin Med

Self Cite

View full text Add to dashboard Cite

BackgroundRetinal ischemia is a retinal disorder related to retinal vascular occlusion, glaucoma, diabetic retinopathy and age-related macular degeneration. The study aimed to evaluate the protective effects and underlying mechanisms of Chi-Ju-Di-Huang-Wan (CJDHW) against retinal ischemia in rats.MethodsHigh intraocular pressure (HIOP)-induced retinal ischemia was established in Wistar rats by raising their intraocular pressure to 120 mmHg for 60 min with in an eye whose anterior chamber was cannulated with a 30-guage needle adapted to a normal saline bottle through an intravenous line. This ischemic insult was followed by 1 or 7 days of reperfusion. The effects of CJDHW were studied by (i) electroretinogram (ERG); (ii) real-time polymerase chain reaction to determine the retinal mRNA levels of Thy-1 and matrix metalloproteinase-9 (MMP-9); (iii) Western blot analysis to determine the retinal protein levels of B cell lymphoma 2 (Bcl-2), heme oxygenase-1 (HO-1), phosphorylated-p38 mitogen-activated protein kinase (P-p38 MAPK) and MMP-9; (iv) hematoxylin and eosin (HE) staining; (v) fluorogold retrograde labeling; and (vi) terminal deoxynucleotidyl-transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) apoptosis assay. Moreover, after fixation with 4 % paraformaldehyde and 30 % sucrose, the isolated retinas were sectioned and immunolabeled with goat anti-choline acetyltransferase (ChAT) polyclonal antibody, mouse anti-vimentin monoclonal antibody and rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal antibody. The retinal sections were then incubated with rhodamine-conjugated rabbit anti-goat antibody, fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG or FITC-conjugated goat anti-rabbit IgG. A daily oral intake of 3 mL of water (vehicle; Group 2) or CJDHW (2.8 or 4.2 g/kg/day; CJDHW2.8 or CJDHW4.2; Group 3 or 4) was given for 7 consecutive days either before (preischemic drug administration) or after HIOP-induced retinal ischemic injury (postischemic drug administration). In Group 5, an intravitreal injection of 4 μL of 0.5 mM SB203580 (p38 MAPK inhibitor) was performed on the ischemic eye 15 min before retinal ischemia. The control rats received a sham procedure (Group 1) where the saline reservoir was not raised.ResultsThe ischemia-induced changes (Group 2) were significantly modulated by pretreating the rats with 4.2 g/kg/day of CJDHW (Group 4; ERG: P < 0.001 on I/R day 7; HE stain: P < 0.001 on I/R day 7; TUNEL: P = 0.05 on I/R day 7; retrograde labeling: P = 0.007 on I/R day 7; Thy-1 mRNA: P = 0.02; MMP-9 mRNA: P < 0.001; Bcl-2 protein: P = 0.02; HO-1 protein: P = 0.03; P-p38 MAPK protein: P < 0.001; MMP-9 protein: P = 0.02). These modulations included the following features (Group 2 vs. 4), increased ERG b-wave amplitudes (0.38 ± 0.04 vs. 0.81 ± 0.03), increased inner retinal thickness (45.08 ± 2.85 vs. 67.98 ± 5.48 μm), increased ChAT immunolabeling, decreased vimentin/GFAP immunoreactivity, less numerous apoptotic cells in the ganglion cell layer (1.40 ± 0.55 vs. 0.60 ± 0.55), an...

show abstract

“… 5 Translumenal Nd:YAG laser has been used to photodisrupt obstructive arterial emboli with promising visual outcomes; yet, significant vitreous hemorrhage, collateral tissue damage, and the potential for emboli fragmentation remain. 6 – 8 …”

Section: Discussionmentioning

confidence: 99%

Surgical Embolectomy for Fovea-Threatening Acute Retinal Artery Occlusion

Almeida

Mammo

Chin

et al. 2016

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

Supplemental Digital Content is Available in the Text.The authors describe a surgical technique to facilitate the exposure and retrieval of embolus in cases of fovea-threatening retinal artery occlusion without a patent cilioretinal artery. The authors include a number of surgical pearls based on our experience that may facilitate intraocular emboli retrieval and minimize the common complication of vitreous hemorrhage associated with retinal embolectomy.

show abstract

EMBOLUS-INDUCED BRANCH RETINAL ARTERY OCCLUSION WITH A PRESENTING BEST-CORRECTED VISUAL ACUITY OF <6/12 AND VISUAL FIELD DEFECT

Abstract: Conclusively, TYE is a safe and effective procedure that can be used to treat eyes with embolus-induced branch retinal artery occlusion with a presenting best-corrected visual acuity of <6/12 and visual defect.

Cited by 7 publications

References 4 publications

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2

Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase

Surgical Embolectomy for Fovea-Threatening Acute Retinal Artery Occlusion

Contact Info

Product

Resources

About